期刊
ACS NANO
卷 13, 期 11, 页码 13127-13135出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.9b05974
关键词
Nanovaccine; nanoscale coordination polymer; Nod1 agonist; checkpoint blockade; cancer immunotherapy
类别
资金
- National Basic Research Programs of China [2016YFA0201200]
- National Natural Science Foundation of China [81602181, 51525203, 51761145041]
- Suzhou Municipal Science and Technology Project [SYS201759]
- Collaborative Innovation Center of Suzhou Nano Science and Technology, Postgraduate Research&Practice Innovation Program of Jiangsu Province [KYCX19_1995]
- Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions
Tumor vaccines to induce robust immunity for cancer treatment have attracted tremendous interests in cancer immunotherapy. In this work, a type of cancer vaccine is prepared by using nanoscale coordination polymer (NCP) formed between Mn2+ ions and a nucleotide oligomerization binding domain 1 (Nod1) agonist, meso-2,6-diaminopimelic acid (DAP), as the organic ligand, to encapsulate a model protein antigen, ovalbumin (OVA). The obtained OVA@Mn-DAP nanoparticles could act as an effective tumor vaccine to promote the maturation of dendritic cells (DCs) as well as their antigen cross-presentation via increasing the cellular uptake of antigen and stimulating Nod1 pathway with DAP. Such OVA@Mn-DAP vaccine could migrate into lymph nodes after local injection, as revealed by in vivo magnetic resonance (MR) and fluorescence imaging. Importantly, vaccination with OVA@Mn-DAP could not only offer prophylactic to protect mice from challenged B16-OVA tumors but also result in significant therapeutic effect to inhibit growth of already-established tumors if in combination with anti-programmed cell death protein 1 antibody (alpha-PD-1) immune checkpoint blockade therapy. Therefore, this work presents an innovative platform to construct effective nanovaccine for tumor immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据